(Reuters) -Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. The drugmaker also forecast third-quarter adjusted earnings per share in the range of $1.74 to $1.78, according to the filing. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Harshita Mary Varghese and Aditya Soni June 15 (Reuters) - Fox Corp is buying…
राजस्थान की प्रतिभाओं, उद्योग जगत के दिग्गजों और नवाचार के नायकों का होगा भव्य सम्मान…
(Corrects paragraph 11 to remove reference to Tubi as Fox's only streaming platform) By Harshita…
By Harshita Mary Varghese and Aditya Soni June 15 (Reuters) - Fox Corp is buying…
By Harshita Mary Varghese and Aditya Soni June 15 (Reuters) - Fox Corp is buying…
पद्मिनी कोल्हापुरे ने किया सम्मानित, घरेलू डिजिटल आय के क्षेत्र में नवाचार और वित्तीय सशक्तिकरण…